EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients

Jeanne M Chen iD, Richard S Mangus iD, Asif A Sharfuddin, John A Powelson, Muhammad S Yaqub, Oluwafisayo O Adebiyi iD, Muhammad Y Jan, Andrew J Lutz, Jonathan A Fridell iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.70050 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Jeanne M Chen and 8 co-authors. Institution: Department of Pharmacy, IU Health, Indianapolis, Indiana, USA. Major MEDLINE topics: Basiliximab, Pancreas Transplantation, Immunosuppressive Agents, Graft Rejection. Cited 5 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

This single‐center retrospective study was designed to evaluate the use of basiliximab as an alternative rescue maintenance immunosuppression in situations where standard maintenance immunosuppression is not tolerated after a pancreas transplant. All pancreas transplants performed between January 11, 2006, and January 6, 2022, were reviewed. All recipients received rabbit antithymocyte globulin (rATG) induction with tacrolimus + sirolimus maintenance for simultaneous pancreas and kidney (SPK) and additional low‐dose mycophenolic acid for pancreas transplant alone (PTA). Basiliximab 40mg IV q 4 weeks was either added to or in replacement of adjunct immunosuppression in cases of medication intolerance. All recipients who received ≥3 months of basiliximab with ≥1 year follow‐up were included. 29/557 (5.2%) recipients (5 SPK and 24 PTA) were identified. Median time to switch was 13 months. When compared 1:2 to matched controls on standard immunosuppression, there was no difference in pancreas rejection, allograft loss, or mortality. Eleven recipients had 13 episodes of pancreas rejection at a median of 28 months post conversion. Eight pancreas allografts failed at a median of 28 months post conversion, and there were five deaths—all occurring in PTA, 4/5 occurring ≥1 year after discontinuation of basiliximab. Renal allograft rejection occurred in one SPK and there was one renal allograft loss. Five PTA developed renal failure. Ten remain on basiliximab (2/5 SPK, 8/24 PTA) at a median of 44 months with good pancreas and kidney function; 4 pts > 4 years. Basiliximab can be considered an alternative rescue maintenance strategy in pancreas transplant recipients who failed other conventional agents.

Subjects

MeSH terms (MEDLINE)

BasiliximabPancreas TransplantationImmunosuppressive AgentsGraft RejectionGraft SurvivalHumansRetrospective StudiesMaleFemaleFollow-Up StudiesAdultMiddle AgedRecombinant Fusion ProteinsPrognosisPostoperative ComplicationsRisk FactorsImmunosuppression TherapyInfusions, IntravenousKidney Transplantation

Author keywords

basiliximabimmunosuppressionpancreas transplant

Substances

BasiliximabImmunosuppressive AgentsRecombinant Fusion Proteins

Authors and institutions

  • Department of Pharmacy, IU Health, Indianapolis, Indiana, USA.
  • Department of Surgery, IU Health/Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Nephrology, IU Health/Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID profiles: Jeanne M Chen, Richard S Mangus, Oluwafisayo O Adebiyi, Jonathan A Fridell

Cite

APA

Chen, J. M., Mangus, R. S., Sharfuddin, A. A., Powelson, J. A., Yaqub, M. S., Adebiyi, O. O., Jan, M. Y., Lutz, A. J., & Fridell, J. A. (2024). The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70050

Vancouver

Chen JM, Mangus RS, Sharfuddin AA, Powelson JA, Yaqub MS, Adebiyi OO, et al. The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.70050

BibTeX
@article{Chen2024,
  author = {Chen, Jeanne M and Mangus, Richard S and Sharfuddin, Asif A and Powelson, John A and Yaqub, Muhammad S and Adebiyi, Oluwafisayo O and Jan, Muhammad Y and Lutz, Andrew J and Fridell, Jonathan A},
  title = {The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.70050}
}
Start for free →